MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning

Norihito Sasaki, Mitsushige Murata, Yiru Guo, Su Hyun Jo, Andreas Ohler, Masaharu Akao, Brian O'Rourke, Rui Ping Xiao, Roberto Bolli, Eduardo Marbán

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Background - MCC-134 (1-[4-(H-imidazol-1-yl)benzoyl]-N-methylcyclobutane-carbothioamide), a newly developed analog of aprikalim, opens surface smooth muscle-type ATP-sensitive potassium (KATP) channels but inhibits pancreatic KATP channels. However, the effects of MCC-134 on cardiac surface KATP channels and mitochondrial KATP (mitoKATP) channels are unknown. A mixed agonist/blocker with differential effects on the two channel types would help to clarify the role of KATP channels in cardioprotection. Methods and Results - To index mitoKATP channels, we measured mitochondrial flavoprotein fluorescence in rabbit ventricular myocytes. MCC-134 alone had little effect on basal flavoprotein fluorescence. However, MCC-134 inhibited diazoxide-induced flavoprotein oxidation in a dose-dependent manner (EC50=27 μmol/L). When ATP was included in the pipette solution, MCC-134 slowly activated surface KATP currents with some delay (>10 minutes). These results indicate that MCC-134 is a mitoKATP channel inhibitor and a surface KATP channel opener in native cardiac cells. In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. These results were reproducible in both rabbit and mouse myocytes. MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. Conclusions - A single drug, MCC-134, opens surface KATP channels but blocks mitoKATP channels; the fact that this drug inhibits preconditioning reaffirms the primacy of mitOKATP rather than surface KATP, channels in the mechanism of cardioprotection.

Original languageEnglish
Pages (from-to)1183-1188
Number of pages6
JournalCirculation
Volume107
Issue number8
DOIs
Publication statusPublished - 2003 Mar 4
Externally publishedYes

Fingerprint

KATP Channels
Diazoxide
Flavoproteins
Muscle Cells
Ischemia
Fluorescence
MCC 134
Rabbits
Ischemic Preconditioning
Pharmaceutical Preparations
Smooth Muscle
Cell Death
Adenosine Triphosphate
Myocardial Infarction

Keywords

  • Ischemia
  • Myocardial infarction
  • Potassium

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning. / Sasaki, Norihito; Murata, Mitsushige; Guo, Yiru; Jo, Su Hyun; Ohler, Andreas; Akao, Masaharu; O'Rourke, Brian; Xiao, Rui Ping; Bolli, Roberto; Marbán, Eduardo.

In: Circulation, Vol. 107, No. 8, 04.03.2003, p. 1183-1188.

Research output: Contribution to journalArticle

Sasaki, Norihito ; Murata, Mitsushige ; Guo, Yiru ; Jo, Su Hyun ; Ohler, Andreas ; Akao, Masaharu ; O'Rourke, Brian ; Xiao, Rui Ping ; Bolli, Roberto ; Marbán, Eduardo. / MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning. In: Circulation. 2003 ; Vol. 107, No. 8. pp. 1183-1188.
@article{48ff000844aa49dbaa41e278a1b9afb4,
title = "MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning",
abstract = "Background - MCC-134 (1-[4-(H-imidazol-1-yl)benzoyl]-N-methylcyclobutane-carbothioamide), a newly developed analog of aprikalim, opens surface smooth muscle-type ATP-sensitive potassium (KATP) channels but inhibits pancreatic KATP channels. However, the effects of MCC-134 on cardiac surface KATP channels and mitochondrial KATP (mitoKATP) channels are unknown. A mixed agonist/blocker with differential effects on the two channel types would help to clarify the role of KATP channels in cardioprotection. Methods and Results - To index mitoKATP channels, we measured mitochondrial flavoprotein fluorescence in rabbit ventricular myocytes. MCC-134 alone had little effect on basal flavoprotein fluorescence. However, MCC-134 inhibited diazoxide-induced flavoprotein oxidation in a dose-dependent manner (EC50=27 μmol/L). When ATP was included in the pipette solution, MCC-134 slowly activated surface KATP currents with some delay (>10 minutes). These results indicate that MCC-134 is a mitoKATP channel inhibitor and a surface KATP channel opener in native cardiac cells. In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. These results were reproducible in both rabbit and mouse myocytes. MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. Conclusions - A single drug, MCC-134, opens surface KATP channels but blocks mitoKATP channels; the fact that this drug inhibits preconditioning reaffirms the primacy of mitOKATP rather than surface KATP, channels in the mechanism of cardioprotection.",
keywords = "Ischemia, Myocardial infarction, Potassium",
author = "Norihito Sasaki and Mitsushige Murata and Yiru Guo and Jo, {Su Hyun} and Andreas Ohler and Masaharu Akao and Brian O'Rourke and Xiao, {Rui Ping} and Roberto Bolli and Eduardo Marb{\'a}n",
year = "2003",
month = "3",
day = "4",
doi = "10.1161/01.CIR.0000051457.64240.63",
language = "English",
volume = "107",
pages = "1183--1188",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - MCC-134, a single pharmacophore, opens surface ATP-sensitive potassium channels, blocks mitochondrial ATP-sensitive potassium channels, and suppresses preconditioning

AU - Sasaki, Norihito

AU - Murata, Mitsushige

AU - Guo, Yiru

AU - Jo, Su Hyun

AU - Ohler, Andreas

AU - Akao, Masaharu

AU - O'Rourke, Brian

AU - Xiao, Rui Ping

AU - Bolli, Roberto

AU - Marbán, Eduardo

PY - 2003/3/4

Y1 - 2003/3/4

N2 - Background - MCC-134 (1-[4-(H-imidazol-1-yl)benzoyl]-N-methylcyclobutane-carbothioamide), a newly developed analog of aprikalim, opens surface smooth muscle-type ATP-sensitive potassium (KATP) channels but inhibits pancreatic KATP channels. However, the effects of MCC-134 on cardiac surface KATP channels and mitochondrial KATP (mitoKATP) channels are unknown. A mixed agonist/blocker with differential effects on the two channel types would help to clarify the role of KATP channels in cardioprotection. Methods and Results - To index mitoKATP channels, we measured mitochondrial flavoprotein fluorescence in rabbit ventricular myocytes. MCC-134 alone had little effect on basal flavoprotein fluorescence. However, MCC-134 inhibited diazoxide-induced flavoprotein oxidation in a dose-dependent manner (EC50=27 μmol/L). When ATP was included in the pipette solution, MCC-134 slowly activated surface KATP currents with some delay (>10 minutes). These results indicate that MCC-134 is a mitoKATP channel inhibitor and a surface KATP channel opener in native cardiac cells. In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. These results were reproducible in both rabbit and mouse myocytes. MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. Conclusions - A single drug, MCC-134, opens surface KATP channels but blocks mitoKATP channels; the fact that this drug inhibits preconditioning reaffirms the primacy of mitOKATP rather than surface KATP, channels in the mechanism of cardioprotection.

AB - Background - MCC-134 (1-[4-(H-imidazol-1-yl)benzoyl]-N-methylcyclobutane-carbothioamide), a newly developed analog of aprikalim, opens surface smooth muscle-type ATP-sensitive potassium (KATP) channels but inhibits pancreatic KATP channels. However, the effects of MCC-134 on cardiac surface KATP channels and mitochondrial KATP (mitoKATP) channels are unknown. A mixed agonist/blocker with differential effects on the two channel types would help to clarify the role of KATP channels in cardioprotection. Methods and Results - To index mitoKATP channels, we measured mitochondrial flavoprotein fluorescence in rabbit ventricular myocytes. MCC-134 alone had little effect on basal flavoprotein fluorescence. However, MCC-134 inhibited diazoxide-induced flavoprotein oxidation in a dose-dependent manner (EC50=27 μmol/L). When ATP was included in the pipette solution, MCC-134 slowly activated surface KATP currents with some delay (>10 minutes). These results indicate that MCC-134 is a mitoKATP channel inhibitor and a surface KATP channel opener in native cardiac cells. In cell-pelleting ischemia assays, coapplication of MCC-134 with diazoxide abolished the cardioprotective effect of diazoxide, whereas MCC-134 alone did not alter cell death. These results were reproducible in both rabbit and mouse myocytes. MCC-134 also attenuated the effect of ischemic preconditioning against myocardial infarction in mice, consistent with the results of cell-pelleting ischemia assays. Conclusions - A single drug, MCC-134, opens surface KATP channels but blocks mitoKATP channels; the fact that this drug inhibits preconditioning reaffirms the primacy of mitOKATP rather than surface KATP, channels in the mechanism of cardioprotection.

KW - Ischemia

KW - Myocardial infarction

KW - Potassium

UR - http://www.scopus.com/inward/record.url?scp=0037418249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037418249&partnerID=8YFLogxK

U2 - 10.1161/01.CIR.0000051457.64240.63

DO - 10.1161/01.CIR.0000051457.64240.63

M3 - Article

VL - 107

SP - 1183

EP - 1188

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -